PEG-Loxenatide (0.2 mg weekly) significantly cut HbA1c, improved TIR, and cardiometabolic health in T2DM.

Type 2 Diabetes Mellitus (T2DM) often remains poorly controlled despite diet, exercise, and conventional glucose-lowering medications, leading to long-term complications. Current treatments may not adequately address both glycemic control and associated cardiometabolic risks. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer a promising therapeutic avenue by enhancing glucose-dependent insulin secretion and improving satiety. This study investigates the real-world efficacy of polyethylene glycol loxenatide (PEG-Loxe), a long-acting GLP-1RA, in improving glycemic control and cardiometabolic parameters in patients with inadequately controlled T2DM.

This multicenter, prospective cohort study enrolled 246 patients with Type 2 Diabetes Mellitus (T2DM) and inadequate glycemic control (HbA1c >7.5%). Participants, already on stable diet, exercise, and glucose-lowering medications for at least 8 weeks, received PEG-Loxe 0.2 mg once weekly as an add-on therapy for 12 weeks. Glycemic profiles, including 24-hour mean blood glucose (MBG), glucose variability (SDBG, CV), time in range (TIR), time above range (TAR), and time below range (TBR), were assessed using the Abbott FreeStyle Libre FGM system. Standardized meal tests measured glucose, HbA1c, insulin, C-peptide, and glucagon pre- and post-treatment.